Delving into the Latest Updates on Band Therapeutics LLC with Synapse

Overview

Tags

Neoplasms

Congenital Disorders

Hemic and Lymphatic Diseases

Aptamers

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Aptamers	4
Small molecule drug	1

Top 5 Target	Count

vWF(Von willebrand factor)	1
IL-23(Interleukin-23)	1
GPC3(Glypican-3)	1
HER3(Receptor tyrosine-protein kinase erbB-3)	1
LRRC15(Leucine-rich repeat-containing protein 15)	1

Study BT200-01 is a first in human (FIH) study in male and female normal human volunteers (NHVs) that uses an Integrated Protocol Design. This Phase 1 study will comprise 4 sub-parts: Part A, a single ascending dose (SAD) study; Part B, a multiple ascending dose (MAD) study; Part C, a desmopressin challenge study to explore (i) whether desmopressin could be used as an antidote, and/or (ii) whether desmopressin stimulated vonWillebrand Factor (VWF) release is overcome with increasing BT200 doses; and Part D, a relative bioavailability (BA) study.
The primary objective of this study is to assess the safety and tolerability profile of BT200 in NHVs.

Start Date07 Oct 2019

Sponsor / Collaborator

Band Therapeutics LLC

100 Clinical Results associated with Band Therapeutics LLC

Login to view more data

0 Patents (Medical) associated with Band Therapeutics LLC

Login to view more data

100 Deals associated with Band Therapeutics LLC

Login to view more data

100 Translational Medicine associated with Band Therapeutics LLC

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

Preclinical

Phase 3 Clinical

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Rondaptivon Pegol ( vWF )	Von Willebrand Disease, Type 2 More	Phase 3
Anti-GPC3 therapy(Band Therapeutics, LLC) ( GPC3 )	Neoplasms More	Preclinical
Anti-IL-23 therapy(Band Therapeutics, LLC) ( IL-23 )	Neoplasms More	Preclinical
Anti-Her3 therapy(Band Therapeutics, LLC) ( HER3 )	Neoplasms More	Discovery
Anti-LRRC15 therapy(Band Therapeutics, LLC) ( LRRC15 )	Neoplasms More	Discovery